



Form PTO-1449

Attorney's Docket No.  
39766-0142AApplication Serial No.  
09/602,800

## INFORMATION DISCLOSURE STATEMENT

Applicant(s) David B. AGUS, et al.

(use several sheets if necessary)

Filing Date:  
June 23, 2000Group Art Unit:  
1642

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
h	1.	Agus et al., "Efficacy and safety of single pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy", ASCO Meeting 2005, Abstract #4624, Session: Genitourinary Cancer, Format: General Poster Sessions, American Society of Clinical Oncology
h	2.	de Bono et al., "An open label, phase II, multicenter, study to evaluate the efficacy of pertuzumab (P) in chemotherapy na? patients (pts) with Hormone Refractory Prostate Cancer (HRPC)", ASCO Meeting 2005, Abstract #4609, Session: Genitourinary Cancer, Format: General Poster Sessions, American Society of Clinical Oncology

EXAMINER:	DATE CONSIDERED: 7/14/05
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2133919 v1	